Compared to full-length cyclin D1, the cyclin D1b variant was significantly deficient in its ability to repress AR-dependent expression of the prostate specific antigen (PSA) mRNA expression in prostate cancer cells, a target gene used clinically to monitor prostate growth and progression. Here, KLK3 is linked to prostate carcinoma.